16Oct/18

Roche and SQZ Biotech Expand Cell Therapy Partnership to Develop Antigen Presenting Cells

SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, is expanding its collaboration with Roche in cellular therapy. Under the terms, SQZ and Roche will jointly develop andRead More…

12Sep/18

Chasing top HIV players, Merck scores FDA approval for 2 new drugs

After marquee HIV drug approvals last year for Gilead and GlaxoSmithKline, Merck will follow into the crowded market with two new meds. The drugmaker scored FDA approvals for a new non-nucleoside reverse transcriptase inhibitor calledRead More…

13Aug/18

FDA Grants Breakthrough Therapy Designation For Food Allergy Med

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Genentech’s,Xolair (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies.Read More…

11Jul/18

Mylan Launches Generic Version Of The Novartis Exelon Patch

Mylan N.V. today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis’ Exelon Patch. Mylan received final approval fromRead More…